Cytokinetics to Participate in March Investor Conferences
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses [Yahoo! Finance]
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]